濮阳东方医院割包皮费用价格(濮阳东方医院男科治早泄技术很不错) (今日更新中)

SAN FRANCISCO, Jan. 26 (Xinhua) -- Global tablet shipments reached nearly 27 million units in the fourth quarter of 2011 with Android jumping to a record share of 39 percent, said a new research released on Thursday.According to the research by consulting firm Strategy Analytics, global tablet shipments reached a record high of 26.8 million units in the last quarter of 2011, surging 250 percent from 10.7 million units in the same period a year earlier.Android captured a record 39 percent share of global tablet shipments, rising from 29 percent in the year-ago quarter.Global Android tablet shipments tripled annually to 10.5 million units in the last three months of 2011 and the platform so far is relatively popular with tablet manufacturers, said the research.However, Apple shipped 15.4 million iPads worldwide and maintained its market leadership with 58 percent share during the fourth quarter last year."Apple shrugged off the much-hyped threat from entry-level Android models this quarter," Peter King, director at Strategy Analytics, said in a statement.The research found Microsoft captured a mere 1.5 percent global tablet share in the quarter, noting that "the upcoming release of Windows 8 this year cannot come quickly enough for Microsoft, so its hardware partners can start competing more effectively in the tablet space."In the full year of 2011, global tablet shipments hit 66.9 million units, increasing by 260 percent from 18.6 million units in 2010, according to the research.Consumers are increasingly buying tablets in preference to netbooks and even entry-level notebooks or desktops, said the research.

WASHINGTON, Oct. 13 (Xinhua) -- In a trial that included about 35,000 men, those who were randomized to receive daily supplementation with vitamin E had a significantly increased risk of prostate cancer, according to a study published this week in the Journal of the American Medical Association.The study followed more than 35,533 men 50 or older at 427 sites in the United States, Canada and Puerto Rico. The men were divided into four groups who took daily doses of 400 international units of Vitamin E and 200 micrograms of selenium; Vitamin E and a placebo that looked like selenium; selenium and a placebo that looked like Vitamin E; or two placebos. The recommended daily intake of Vitamin E is about 22.4 international units.The researchers from the Cleveland Clinic found that the rate of prostate cancer detection was greater in all treatment groups when compared with placebo but was statistically significant only in the vitamin E alone group -- a 17 percent increased rate of prostate cancer detection. The difference in rates of prostate cancer between vitamin E and placebo became apparent during the participants' third year in the trial. The elevated risk estimate for vitamin E was consistent across both low- and high-grade disease."The observed 17 percent increase in prostate cancer incidence demonstrates the potential for seemingly innocuous yet biologically active substances such as vitamins to cause harm. The lack of benefit from dietary supplementation with vitamin E or other agents with respect to preventing common health conditions and cancers or improving overall survival, and their potential harm, underscore the need for consumers to be skeptical of health claims for unregulated over-the-counter products in the absence of strong evidence of benefit demonstrated in clinical trials," the researchers said.

WASHINGTON, Dec. 12 (Xinhua) -- British scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth. The findings, published Monday in the U.S. journal Cancer Cell, reveal how cancer cells grow faster by producing their own blood vessels.Cancer cells gain the nutrients they need by producing proteins that make blood vessels grow, helping deliver oxygen and sugars to the tumor. These proteins are vascular growth factors like VEGF -- the target for the anti-cancer drug Avastin. Making these proteins requires the slotting together of different parts of genes, a process called splicing.Scientists at the University of West England and the University of Bristol discovered that mutations in one specific cancer gene can control how splicing is balanced, allowing a master switch in the cell to be turned on. This master switch of splicing makes cancer cells grow faster, and blood vessels to grow more quickly, as they alter how VEGFs are put together.In experimental models, the researchers found that by using new drugs that block this master switch they prevented blood vessel growth and stopped the growth of cancers."The research clearly demonstrates that it may be possible to block tumor growth by targeting and manipulating alternative splicing in patients, adding to the increasingly wide armory of potential anti-cancer therapies," the authors said.

BEIJING, Oct. 11 (Xinhuanet) -- Debates in the medical field developed on Monday as a U.S. government panel recommended that men of all ages should stop getting prostate cancer blood screenings.The United States Preventive Services examined all the evidence and found little if any reduction in deaths from routine P.S.A. screening and suggested that the test does more harm than good to healthy men.The P.S.A. test for prostate cancer, a blood test to screen for a protein that may indicate cancer, has become widely used because it can help detect tiny tumors at a very early sta ge, when they are theoretically most treatable.Unfortunately, according to the task force, the vast majority of the results are false-positives: the men don’t actually have cancer. And most of those found to have cancerous cells would not suffer ill effects because their cancer is so slow-growing that it would not cut short their lives. Those with faster-growing cancers may also not be helped if the cancer is extremely aggressive.After the recommendation came out last week, many prostate cancer specialists have been pushing back.Urologist Dr. Mark DeGuenther said this recommendation is more about saving money than saving lives. He said death rates from prostate cancer have dropped 40 percent since men began getting screened at age 40 and he says it will save taxpayers and patients more money in the long run to diagnose and treat cancers earlier rather than wait and have to provide expensive care for advanced stage cancers."We all agree that we've got to do a better job of figuring out who would benefit from P.S.A. screening," said Dr. Scott Eggener, a prostate cancer specialist at the University of Chicago. "But a blanket statement of just doing away with it altogether ... seems over-aggressive and irresponsible."Dr. Deepak Kapoor, chairman and chief executive of Integrated Medical Professionals, which includes the nation's largest urology practice, said "We will not allow patients to die, which is what will happen if this recommendation is accepted."That task force's recommendation isn't final - it's a draft open for public debate. And obviously the debate is already under way.

NEW YORK, Oct. 3 (Xinhua) -- For the 34-year-old Alexis Steinman, Oct. 3 would have been a great day, because her father Ralph Steinman was announced winner of the 2011 Nobel Prize in Physiology or Medicine.But as she talked to Xinhua at the Rockefeller University where his father worked, she said the day was rather "bittersweet"."This is the moment, but my Dad was not here," said Alexis, trying to hold her tears.The Canadian-born cell biologist Ralph Steinman died of pancreatic cancer on Friday at the age of 68, three days before he was announced the joint winner along with Prof. Bruce Beutler and Prof. Jules Hoffman for the Nobel Prize in Physiology or Medicine."We even talked about the Nobel Prize days before his death," Alexis added."We were like 'OK Dad, I know things aren't going well but the Nobel, they are going to announce it next Monday'. And he was like 'I know I have got to hold out for that. They don't give it to you if you have passed away,'" she said."It's really impossible to describe how our family is feeling right now. We're devastated to have lost Ralph,"Steinman' s son Adam Steinman told reporters at the press conference at Rockefeller University. "We're so incredibly proud of Dad for receiving this wonderful honor ... We know he will live on through his scientific contributions," he said.Rockefeller University president Marc Tessier-Lavigne told reporters during Monday's press conference that the university only heard of Steinman's death from the family about half an hour after news of the Nobel prize came out from Sweden."We are all deeply saddened by his death, " said Tessier- Lavigne , adding that Steinman had been treating himself with a groundbreaking therapy based on his research into the body's immune system.He said Steinman's research has laid the foundation for numerous discoveries in the critically important field of immunology, and it has led to innovative new approaches in how people treat cancer, infectious diseases and disorders of the immune system.Steinman's first student and close colleague Michel Nussenzweig told the press conference packed with reporters, students and professors that "one of the interesting things about Ralph and his discovery is that no one believes it for a really long time.""What was amazing about Ralph was that he just knew that, even though nobody else believed it, this was really important, and he persisted, and finally after a very long time, everyone just found out it was true," Nussenzweig said."Ralph worked until last week. His dream was to use his discovery to make vaccines and it is a dream that is pretty close, and we are all continuing to work to make that come true," he added.The Nobel Foundation made a statement after learning Steinman's death, saying that the decision to award the prize to the Canadian scientist would remain unchanged despite his death, and the prize money will be transferred to his estate.

来源：资阳报